Development of a lymphoma-on-chip model for testing therapeutic strategies

Project Details

Description

We aim to revolutionize lymphoma research by developing a groundbreaking 'lymphoma-on-chip' model, providing a unique platform to study invasion mechanisms and test novel therapies. Our innovative approach focuses on recreating the complex lymph node microenvironment, addressing a critical gap in current research for more effective lymphoma treatments.

Layman's description

Revolutionizing Lymphoma Treatment with Cutting-Edge Technology
In collaboration with a key industry partner, our project focuses on developing an innovative 'lymphoma-on-chip' model, a groundbreaking platform that mimics the intricate environment within the human body to study and address lymphoma invasion mechanisms. This marks a pivotal step forward in public-private partnership, combining expertise for a common goal: improving lymphoma treatments.

Societal Impact and Urgency for Innovation
Lymphoma, particularly Diffuse Large B-cell Lymphoma (DLBCL), poses a significant health challenge. In the Netherlands alone, 1500 new DLBCL cases are diagnosed annually, with a concerning 40% mortality rate within 5 years despite existing treatments. This highlights the critical need for innovative approaches to better understand and combat lymphoma, underscoring the urgency of our project.

Innovative Approach for Improved Understanding
Our project addresses a current research gap by recreating the complex microenvironment of lymph nodes. Unlike conventional therapies targeting only tumor cells, our 'lymphoma-on-chip' model allows us to study how lymphoma develops and grows within this intricate setting. By incorporating lymph node stromal cells, we aim to unravel the role of fibroblasts and endothelial cells in DLBCL progression, paving the way for more effective and targeted treatments.

Anticipated Deliverables and Impact
As we progress through our innovative experimental 'waterfall' approach, we will confirm the invasion capabilities of lymphoma cells in response to different stimuli. The inclusion of lymph node stromal cells and testing candidate drugs will follow, providing a comprehensive understanding of invasion mechanisms and potential therapeutic interventions. The deliverables from this project will not only contribute to scientific knowledge but also hold the promise of informing future treatments, ultimately improving outcomes for individuals diagnosed with DLBCL. Our commitment is not just to advancement in research but, more importantly, to making a tangible impact on the lives of those affected by lymphoma.
AcronymLYMPHOMACHIPTHERA
StatusActive
Effective start/end date1/02/202431/05/2025